Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 3

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 4NIH 3

Study Type

Interventional 4

Sponsor

Cancer Type

Other solid neoplasm 3Breast 1

Conditions

Solid Tumor Cancer 2Solid Tumours 1Breast Neoplasms 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × ispinesib × Clear all
NCT00607841 2019-05-06

A Study of Ispinesib in Metastatic Breast Cancer

Cytokinetics

Phase 1 Terminated
16 enrolled
Breast

Breast Neoplasms

NCT00136578 2017-09-25

Ispinesib In Combination With Carboplatin In Patients With Solid Tumors

GlaxoSmithKline

Phase 1 Completed
30 enrolled
Other solid neoplasm

Solid Tumours

NCT00119171 2008-10-16

Ispinesib In Combination With Capecitabine In Patients With Solid Tumors

GlaxoSmithKline

Phase 1 Completed
30 enrolled
Other solid neoplasm

Solid Tumor Cancer

NCT00169520 2008-10-16

SB-715992 In Combination With Docetaxel In Patients With Solid Tumors

GlaxoSmithKline

Phase 1 Completed
30 enrolled
Other solid neoplasm

Solid Tumor Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡